ESMO 2022 | SWOG S1801: Escalation vs. deescalation of immunotherapy for melanoma

Sapna Patel, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the SWOG S1801 trial (NCT03698019) of neoadjuvant vs adjuvant immunotherapy for patients with resectable melanoma and explains in which situation patients could undergo a de-escalation in immunotherapy and in which situation patients should undergo an escalation in immunotherapy. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.